	US 11,857,602 B2
	Growth hormone antagonist and anti-cancer composition combination therapy
Richard S. Brody, Columbus, OH (US); Thomas J. Zupancic, Powel, OH (US); Uday Sandbhor, Hilliard, OH (US); John J. Kopchick, Athens, OH (US); and Reetobrata Basu, Athens, OH (US)
Filed by Molecular Technologies Laboratories LLC, Galena, OH (US); and Ohio University, Athens, OH (US)
Filed on Aug. 25, 2021, as Appl. No. 17/411,497.
Application 17/411,497 is a continuation in part of application No. 16/903,644, filed on Jun. 17, 2020, granted, now 11,452,763.
Claims priority of provisional application 62/862,222, filed on Jun. 17, 2019.
Prior Publication US 2022/0040266 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/27 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 38/27 (2013.01) [A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)]

8 Claims

1. A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising:

(a) a modified human growth hormone receptor antagonist, wherein the human growth hormone receptor antagonist comprises:

(i) human growth hormone receptor antagonist G120K, wherein two amino acids of human growth hormone receptor antagonist G120K have been changed to cysteine, wherein the two amino acids changed to cysteine are T142 and H151, and wherein the human growth hormone receptor antagonist G120K-H151C-T142-C has a DNA sequence of SEQ ID NO: 3, and an amino acid sequence of SEQ ID NO: 4; and

(ii) polyethylene glycol molecule conjugated to each substituted cysteine in the human growth hormone receptor antagonist G120K-H151C-T142C, wherein the polyethylene glycol molecules conjugated to the two amino acids changed to cysteine are two 4.5 kDa branched polyethylene glycols each containing three carboxylate anions; and

(b) an anti-cancer composition.